The Indian Patent Office set aside Abbott Biotechnology’s Humira patent after Glenmark’s pre-grant opposition, citing lack of inventive step and insufficient disclosure. This legal dispute underscores ongoing challenges to Humira patents both in India and globally.
Read more about Drug Humira turns Rheumatic for Abbott Biotechnology